Clinical trials
Completed Phase 3 trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,448 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 10 |
| 2002 | 14 |
| 2003 | 30 |
| 2004 | 29 |
| 2005 | 59 |
| 2006 | 57 |
| 2007 | 63 |
| 2008 | 82 |
| 2009 | 70 |
| 2010 | 78 |
| 2011 | 77 |
| 2012 | 82 |
| 2013 | 85 |
| 2014 | 100 |
| 2015 | 87 |
| 2016 | 67 |
| 2017 | 90 |
| 2018 | 82 |
| 2019 | 85 |
| 2020 | 66 |
| 2021 | 51 |
| 2022 | 33 |
| 2023 | 22 |
| 2024 | 17 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 1,448 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 97 |
| Eli Lilly and Company | 87 |
| Hoffmann-La Roche | 86 |
| AstraZeneca | 82 |
| Pfizer | 76 |
| GlaxoSmithKline | 65 |
| Boehringer Ingelheim | 56 |
| Sanofi | 55 |
| Bristol-Myers Squibb | 53 |
| Novo Nordisk A/S | 47 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 99 |
| Carcinoma, Non-Small-Cell Lung | 68 |
| Breast Neoplasms | 58 |
| Pulmonary Disease, Chronic Obstructive | 35 |
| Arthritis, Rheumatoid | 33 |
| Diabetes Mellitus | 32 |
| Neoplasms | 32 |
| Neoplasm Metastasis | 29 |
| Schizophrenia | 28 |
| Carcinoma, Hepatocellular | 26 |
Trials
Showing 1 to 25 of 1,448. Each trial links to its page on Pharma Observatory.
1,348 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.